Free Trial
NASDAQ:GDTC

CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

CytoMed Therapeutics logo
$1.92 +0.03 (+1.32%)
As of 12:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CytoMed Therapeutics Stock (NASDAQ:GDTC)

Key Stats

Today's Range
$1.85
$1.92
50-Day Range
$1.75
$2.31
52-Week Range
$1.20
$4.05
Volume
2,278 shs
Average Volume
83,542 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

CytoMed Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

GDTC MarketRank™: 

CytoMed Therapeutics scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CytoMed Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CytoMed Therapeutics has received no research coverage in the past 90 days.

  • Read more about CytoMed Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    0.86% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 2.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    CytoMed Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CytoMed Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.86% of the float of CytoMed Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CytoMed Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CytoMed Therapeutics has recently decreased by 2.31%, indicating that investor sentiment is improving.
    Receive GDTC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    GDTC Stock News Headlines

    Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
    Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
    See More Headlines

    GDTC Stock Analysis - Frequently Asked Questions

    CytoMed Therapeutics' stock was trading at $3.40 at the beginning of the year. Since then, GDTC stock has decreased by 44.1% and is now trading at $1.90.

    CytoMed Therapeutics (GDTC) raised $10 million in an initial public offering (IPO) on Friday, April 14th 2023. The company issued 2,412,369 shares at $4.00 per share.

    Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that CytoMed Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

    Company Calendar

    Today
    9/05/2025
    Next Earnings (Estimated)
    9/30/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:GDTC
    CIK
    1873093
    Fax
    N/A
    Employees
    N/A
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $5.00
    Low Price Target
    $5.00
    Potential Upside/Downside
    +163.2%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    N/A
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    N/A

    Debt

    Debt-to-Equity Ratio
    0.05
    Current Ratio
    9.89
    Quick Ratio
    9.89

    Sales & Book Value

    Annual Sales
    $50 thousand
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.61 per share
    Price / Book
    3.11

    Miscellaneous

    Outstanding Shares
    N/A
    Free Float
    N/A
    Market Cap
    N/A
    Optionable
    Not Optionable
    Beta
    -0.38

    Social Links

    (Almost)  Everything You Need To Know About The EV Market Cover

    Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

    Get This Free Report

    This page (NASDAQ:GDTC) was last updated on 9/5/2025 by MarketBeat.com Staff
    From Our Partners